Summary of Significant Accounting Policies (Tables)

12 Months Ended

Mar. 02, 2019

Summary of Significant Accounting Policies

Schedule of revenues from description of business

	Year Ended
	March 2,		March 3,		March 4,
	2019		2018		2017
	(52 Weeks)		(52 Weeks)		(53 Weeks)
Retail Pharmacy segment:
Pharmacy sales	$	10,391,539	$	10,328,376	$	11,072,480
Front-end sales		5,215,152		5,348,613		5,538,352
Other revenue		150,461		155,636		155,788
Total Retail Pharmacy segment		15,757,152		15,832,625		16,766,620
Pharmacy Services segment revenue		6,093,688		5,896,669		6,393,884
Intersegment elimination		(211,283)		(200,326)		(232,964)
Total revenue	$	21,639,557	$	21,528,968	$	22,927,540

Schedule of principal classes of products

	Percentage
Product Class	of Sales
Prescription drugs	66.6	%
Over-the-counter medications and personal care	10.8	%
Health and beauty aids	5.0	%
General merchandise and other	17.6	%

Schedule of revenues

In thousands	March 2, 2019
Retail Pharmacy segment:
Pharmacy sales	$	10,391,539
Front-end sales		5,215,152
Other revenue		150,461
Total Retail Pharmacy segment		15,757,152
Pharmacy Services segment		6,093,688
Intersegment elimination		(211,283)
Total revenue	$	21,639,557

Schedule of impact of the Company's adoption of the ASU on the prior period consolidated balance sheet

	Impact of Change in Accounting Policy
	As Reported				Adjusted
In thousands	March 3, 2018		Adjustments		March 4, 2018
Consolidated Balance Sheet:
Accounts receivable, net	$	1,869,100	$	(57,897)	$	1,811,203
Inventories, net		1,799,539		51,121		1,850,660
Deferred tax assets		594,019		(1,784)		592,235
Total assets		8,989,327		(8,560)		8,980,767
Accumulated deficit		(4,282,471)		(8,560)		(4,291,031)
Total shareholders’ equity		1,601,010		(8,560)		1,592,450